Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 137

Sort by

Sort Order Select

Journal Articles

Does stringent cytoreduction improve survival in myeloproliferative chronic myelomonocytic leukemia? a correlative study on the dacota trial.

Blood (2025) 146 (Supplement 1): 791.

https://doi.org/10.1182/blood-2025-791

Published: 2025

Journal Articles

Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline

Blood (2025) 146 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2025-1682

Published: 2025

Journal Articles

Secondary-type acute myeloid leukemia is associated with a higher risk of invasive fungal infection during intensive induction therapy. a correlative study on the ALFA 0702 trial.

Blood (2025) 146 (Supplement 1): 994.

https://doi.org/10.1182/blood-2025-994

Published: 2025

Journal Articles

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

Blood (2025) 146 (Supplement 1): 37.

https://doi.org/10.1182/blood-2025-37

Published: 2025

Journal Articles

Comprehensive mutational profiling and clinical outcome of adults AML with NUP98 rearrangement

Blood (2025) 146 (Supplement 1): 7002.

https://doi.org/10.1182/blood-2025-7002

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Blood (2025) 146 (Supplement 1): 5230.

https://doi.org/10.1182/blood-2025-5230

Published: 2025

Journal Articles

Real-life CD34+CD38- leukemic stem cell (LSC) flow quantification in adult AML at diagnosis independently predicts survival of intensively but not AZA-VEN treated patients: A study of prospective observational ALFA-PPP acute leukemia french association

Blood (2025) 146 (Supplement 1): 3483.

https://doi.org/10.1182/blood-2025-3483

Published: 2025

Journal Articles

Frequency and impact of FLT3-ITD microclones in younger AML patients

Blood (2025) 146 (Supplement 1): 456.

https://doi.org/10.1182/blood-2025-456

Published: 2025

Journal Articles

Real-world patterns of treatment intensity and prognostic model performance in older AML: Insights from the french ALFA-PPP cohort

Blood (2025) 146 (Supplement 1): 454.

https://doi.org/10.1182/blood-2025-454

Published: 2025

Journal Articles

Real life treatments and outcomes of older patients aged more than 60 years with FLT3-mutated acute myeloid leukemia: Report from the multicentric french observational ALFA-PPP study

Blood (2025) 146 (Supplement 1): 449.

https://doi.org/10.1182/blood-2025-449

Published: 2025

Journal Articles

Outcomes of NPM1-mutated AMLs in first hematological relapse and prognostic value of MRD

Blood (2025) 146 (Supplement 1): 5294.

https://doi.org/10.1182/blood-2025-5294

Published: 2025

Journal Articles

Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.

Blood (2025) 146 (Supplement 1): 6386.

https://doi.org/10.1182/blood-2025-6386

Published: 2025

Journal Articles

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Anthony M. Hunter, Mrinal M. Patnaik, Raphael Itzykson, Ruben Mesa, Chatchada Karanes, Yanxia Li, R. Angelo de Claro, Kelly J. Norsworthy, Marc Theoret, Elizabeth Pulte, Eric Padron

Blood (2024) 144 (19): 1987–1992.

https://doi.org/10.1182/blood.2024025648

Published: 2024

Journal Articles

Prognostic Significance of Monocytic-like Phenotype in AML Patients Treated with Venetoclax and Azacytidine

Lin Pierre Zhao, Typhaine Dumas-Rivero, Lauren Barette, Lorea Aguinaga, Arij Cheffai, Pierre Lemaire, Stéphanie Mathis, Clémentine Chauvel, Reinaldo Dal Bello, Emmanuelle Clappier, Matthieu Duchmann, Pierre Fenaux, Marie Sebert, Lionel Ades, Raphael Itzykson

Blood (2024) 144 (Supplement 1): 4316.

https://doi.org/10.1182/blood-2024-203353

Published: 2024

Journal Articles

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Luca Lanino, Anthony M. Hunter, Nico Gagelmann, Marie Robin, Claudia Sala, Daniele Dall'Olio, Carmelo Gurnari, Lorenzo Dall'Olio, Yu-Hung Wang, Lisa Pleyer, Blanca Xicoy, Guillermo Montalban-Bravo, Lee-Yung Shih, Tamanna Haque, Omar Abdel-Wahab, Klaus Geissler, Alex Bataller, Alexandre Bazinet, Manja Meggendorfer, Ilaria Carola Casetti, Elisabetta Sauta, Erica Travaglino, Laura Palomo, Lurdes Zamora, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Esperanza Such, Guillermo Sanz, Anne Sophie Kubasch, Cristina Castilla-Llorente, Claude-Éric Bulabois, Laetitia Souchet, Hussein Awada, Massimo Bernardi, Patrizia Chiusolo, Antonio Curti, Luisa Giaccone, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Elisa Diral, Vladan Vucinic, Gregorio Maria Bergonzi, Maria Teresa Voso, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Elena Riva, Mattia Delleani, Angela Consagra, Francesca Ficara, Armando Santoro, Luciana Carota, Tiziana Sanavia, Cesare Rollo, Ahmad Kiwan, Jennifer VanOudenhove, Piero Fariselli, Najla H. Al Ali, David Sallman, Wolfgang Kern, Guillermo Garcia-Manero, Swapna Thota, Elizabeth A. Griffiths, Matilde Yung Follo, Carlo Finelli, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Rafael Bejar, Felicitas R. Thol, Nicolaus Kröger, Pierre Fenaux, Raphael Itzykson, Timothy Aaron Graubert, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Mrinal M. Patnaik, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2024-200104

Published: 2024

Journal Articles

Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup

Blood (2024) 144 (Supplement 1): 227.

https://doi.org/10.1182/blood-2024-194060

Published: 2024

Journal Articles

Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network

Blood (2024) 144 (Supplement 1): 226.

https://doi.org/10.1182/blood-2024-205457

Published: 2024

Journal Articles

Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study

Blood (2024) 144 (Supplement 1): 2424.

https://doi.org/10.1182/blood-2024-207226

Published: 2024

Journal Articles

IL-1RAP Is a Targetable Surface Antigen in Relapsed/Refractoy AML

Blood (2024) 144 (Supplement 1): 4311.

https://doi.org/10.1182/blood-2024-199673

Published: 2024

Journal Articles

NPM1-mutated AML: how many diseases?

Raphaël Itzykson

Blood (2024) 144 (7): 681–683.

https://doi.org/10.1182/blood.2024025032

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Does stringent cytoreduction improve survival in myeloproliferative chronic myelomonocytic leukemia? a correlative study on the dacota trial.

Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline

Secondary-type acute myeloid leukemia is associated with a higher risk of invasive fungal infection during intensive induction therapy. a correlative study on the ALFA 0702 trial.

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

Comprehensive mutational profiling and clinical outcome of adults AML with NUP98 rearrangement

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Real-life CD34+CD38- leukemic stem cell (LSC) flow quantification in adult AML at diagnosis independently predicts survival of intensively but not AZA-VEN treated patients: A study of prospective observational ALFA-PPP acute leukemia french association

Frequency and impact of FLT3-ITD microclones in younger AML patients

Real-world patterns of treatment intensity and prognostic model performance in older AML: Insights from the french ALFA-PPP cohort

Real life treatments and outcomes of older patients aged more than 60 years with FLT3-mutated acute myeloid leukemia: Report from the multicentric french observational ALFA-PPP study

Outcomes of NPM1-mutated AMLs in first hematological relapse and prognostic value of MRD

Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Prognostic Significance of Monocytic-like Phenotype in AML Patients Treated with Venetoclax and Azacytidine

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup

Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network

Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study

IL-1RAP Is a Targetable Surface Antigen in Relapsed/Refractoy AML

NPM1-mutated AML: how many diseases?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only